1. A 61-year-old man with hypertension on ramipril 10 mg, amlodipine 10 mg, and chlorthalidone 25 mg daily presents with home BP averaging 158/96 mmHg. Adherence is confirmed by urine drug levels. ABPM confirms persistent hypertension. He has no diabetes, no CKD (eGFR 74 mL/min/1.73m2), and no heart failure. Potassium is 4.2 mEq/L. PRA is 0.3 ng/mL/hr (suppressed). His physician considers adding spironolactone 25 mg daily.
Before initiating, the physician reviews potential drug interactions. Which of the following most accurately identifies the pharmacological interaction of greatest clinical concern when adding spironolactone to this specific regimen, and how it should be managed?
A) Spironolactone interacts with amlodipine through CYP3A4 inhibition — spironolactone's active metabolite canrenone is a moderate CYP3A4 inhibitor that raises amlodipine plasma levels by approximately 40%, increasing edema and hypotension risk; amlodipine should be reduced to 5 mg before spironolactone is initiated
B) Spironolactone interacts with chlorthalidone through competitive inhibition at the NCC transporter in the distal convoluted tubule — the two agents antagonize each other's diuretic effects and cannot be safely combined; chlorthalidone must be discontinued before spironolactone is started
C) Spironolactone has no clinically significant interactions with any component of this regimen — it can be added at 25 mg without any monitoring or dose adjustments
D) The primary interaction of clinical concern is hyperkalemia from the combination of spironolactone (which retains potassium by blocking aldosterone-mediated collecting duct excretion) with ramipril (which reduces angiotensin II-mediated aldosterone secretion, further reducing potassium excretion) — the two agents together produce additive potassium retention that exceeds the effect of either alone; management is to check potassium and renal function within 2 weeks of initiating spironolactone, target potassium below 5.5 mEq/L, and counsel the patient to avoid high-potassium foods and potassium supplements; if potassium rises above 5.5 mEq/L, reduce the spironolactone dose or consider a potassium binder; chlorthalidone's potassium-wasting effect partially offsets this risk but does not eliminate it in all patients
E) Spironolactone interacts with ramipril to produce a clinically significant reduction in serum creatinine — the combination of MRA and ACEi causes excessive efferent arteriolar dilation that hyperfiltrates the glomerulus, paradoxically lowering creatinine to subnormal levels; creatinine should be monitored for unexpected falls below 0.6 mg/dL
ANSWER: D
Rationale:
The primary pharmacological interaction when adding spironolactone to a regimen containing an ACEi is additive potassium retention — the most important safety concern requiring proactive management. Ramipril reduces angiotensin II production through ACE inhibition; reduced angiotensin II reduces aldosterone secretion from the adrenal cortex, thereby decreasing aldosterone-mediated potassium excretion in the collecting duct. Spironolactone directly blocks the mineralocorticoid receptor in the collecting duct principal cells, preventing aldosterone from opening potassium-secreting channels (ROMK) — further reducing potassium excretion through a different but convergent mechanism. Together, the two agents produce additive potassium retention that can cause significant hyperkalemia, particularly in patients with even mild CKD (which blunts renal potassium clearance) or in those consuming high-potassium diets. This patient has a potassium of 4.2 mEq/L and normal eGFR — currently in the safe zone — but monitoring at 2 weeks is mandatory. Chlorthalidone's kaliuretic effect (promoting potassium excretion through increased distal tubular flow and sodium delivery) partially offsets the potassium-raising effect of the ACEi-MRA combination, but this offset is incomplete and variable.
Option A: Option A is incorrect because canrenone does not clinically significantly inhibit CYP3A4; this drug interaction does not exist at therapeutic doses.
Option B: Option B is incorrect because spironolactone and chlorthalidone act at different tubular segments through different mechanisms — they do not antagonize each other; in fact their combination is commonly used and their partial offset on potassium is pharmacologically complementary.
Option C: Option C is incorrect because the ACEi-MRA hyperkalemia interaction is clinically significant and requires monitoring.
Option E: Option E is incorrect because the ACEi-MRA combination does not cause hyperfiltration or subnormal creatinine; it may cause a modest acute rise in creatinine from efferent arteriolar dilation reducing intraglomerular pressure, not a fall.
2. A 74-year-old woman with hypertension, stage 3a CKD (eGFR 52 mL/min/1.73m2), and no diabetes presents to the emergency department with BP 202/118 mmHg. She is confused and her husband reports she developed a severe headache earlier today. Neurological exam shows confusion but no focal deficits. Fundoscopy reveals bilateral papilledema and flame hemorrhages. Urinalysis shows 3+ proteinuria. Troponin is normal and ECG shows LVH but no ischemic changes.
IV nicardipine infusion is initiated. After 45 minutes, her MAP has been reduced by 27%. She is now alert, BP is 162/104 mmHg, and the headache has improved.
Which of the following most accurately identifies the error in the BP management so far and the correct next step?
A) The error is using nicardipine — in a patient with CKD, the preferred IV agent for hypertensive emergency is IV labetalol because nicardipine's renal elimination is impaired at eGFR 52, causing accumulation and excessive vasodilation; nicardipine should be switched to labetalol immediately
B) The MAP has been reduced by 27% in 45 minutes — this slightly exceeds the guideline-recommended maximum of 25% MAP reduction in the first hour; the nicardipine infusion rate should be reduced immediately to allow BP to stabilize at its current level; further reduction should proceed toward 160/100–110 mmHg over the next 2–6 hours at a slower rate; the clinical improvement (alertness, headache resolution) is reassuring, but the 27% reduction represents a protocol deviation that increases the risk of cerebral hypoperfusion; close neurological monitoring is required
C) There is no error — a 27% MAP reduction in the first hour is within acceptable parameters for hypertensive encephalopathy; the protocol should continue aggressively toward the long-term target of 130/80 mmHg over the next 2 hours given the severity of the presentation and bilateral papilledema
D) The error is not having started IV furosemide simultaneously — in a patient with CKD and proteinuria, the hypertensive emergency is driven entirely by volume overload; nicardipine addresses only the vasoconstriction component; IV furosemide 80 mg should be added now to address the volume component
E) The error is the route of administration — oral antihypertensives (captopril 25 mg plus chlorthalidone 25 mg) should replace IV nicardipine now that the patient is alert; continued IV therapy in a patient who can take oral medications is unnecessarily aggressive and increases the risk of iatrogenic hypotension
ANSWER: B
Rationale:
The guideline-recommended maximum MAP reduction in the first hour of a hypertensive emergency is 25%. This patient's MAP has been reduced by 27% in 45 minutes — slightly exceeding the safe threshold. While a 2% overshoot may seem minor, the pharmacological rationale for the 25% ceiling is based on the rightward-shifted cerebral autoregulation curve in chronically hypertensive patients: their adapted lower autoregulatory limit is approximately 100–120 mmHg MAP, and any reduction below this limit reduces cerebral blood flow passively, risking watershed infarction. A 27% MAP reduction in a patient presenting with BP 202/118 mmHg (MAP approximately 146 mmHg) brings MAP to approximately 107 mmHg — approaching the lower autoregulatory limit. The clinical improvement (alertness, headache resolution) is reassuring and suggests no ischemic injury has yet occurred, but the infusion rate should be reduced to prevent further over-rapid reduction. The correct next phase is to proceed toward 160/100–110 mmHg over the next 2–6 hours at a controlled rate.
Option A: Option A is incorrect because nicardipine does not require dose adjustment for CKD at eGFR 52 mL/min/1.73m2 — it undergoes primarily hepatic metabolism; and nicardipine is one of the guideline-endorsed preferred agents for hypertensive encephalopathy.
Option C: Option C is incorrect because 27% exceeds the 25% guideline ceiling — it is a protocol deviation; and proceeding aggressively to the long-term target of 130/80 mmHg within 2 hours violates the graduated reduction protocol.
Option D: Option D is incorrect because while volume management is important in hypertensive emergencies with CKD, the diagnosis here is hypertensive encephalopathy — the primary driver is not solely volume overload, and IV furosemide is not the mandated co-treatment for this presentation.
Option E: Option E is incorrect because a patient who has just had a hypertensive emergency with encephalopathy requires continued IV therapy with close titration; oral agents do not provide the precise rate control needed in the first hours.
3. A 56-year-old woman with hypertension and no other medical history is on lisinopril 40 mg and amlodipine 10 mg daily. Her BP has been well controlled at 126/78 mmHg for 2 years. She develops a new dry cough over several weeks that is disturbing her sleep. She confirms the cough is not related to a respiratory illness and it began approximately 3 weeks after her most recent lisinopril refill. Her physician suspects ACEi-associated cough.
Which of the following most accurately identifies the correct management of this patient's ACEi-associated cough, and the pharmacological basis for the adverse effect?
A) Lisinopril should be switched to an ARB (losartan, valsartan, irbesartan, or telmisartan) at an equivalent antihypertensive dose — ACEi-associated cough is caused by bradykinin accumulation in the airway: ACE (kininase II) normally degrades bradykinin; when ACE is inhibited, bradykinin and its metabolite substance P accumulate in the airway mucosa, stimulating sensory C-fiber afferents and triggering a non-productive cough; ARBs block the AT1 receptor rather than the ACE enzyme, do not inhibit bradykinin degradation, and are therefore not associated with cough; the switch eliminates the adverse effect while maintaining RAAS inhibition at equivalent antihypertensive and cardiovascular protective efficacy; cough typically resolves within 1–4 weeks of switching
B) Lisinopril should be continued — ACEi-associated cough resolves spontaneously in most patients within 6–8 weeks of continued therapy as ACE receptors in the airway adapt to chronic inhibition; switching agents is premature at this stage
C) The cough is caused by amlodipine-induced pulmonary edema — CCBs cause interstitial fluid accumulation in the pulmonary vasculature through capillary hydrostatic pressure changes; amlodipine should be discontinued and replaced with a thiazide diuretic to relieve the pulmonary fluid accumulation
D) Lisinopril should be replaced with a direct renin inhibitor (aliskiren) — aliskiren inhibits renin rather than ACE, preserving ACE-mediated bradykinin degradation and eliminating the cough while providing equivalent RAAS inhibition
E) The cough indicates ACEi-induced upper respiratory inflammation that will progress to hypersensitivity pneumonitis if lisinopril is continued; it should be discontinued immediately and replaced with chlorthalidone 25 mg, and pulmonary function testing should be arranged
ANSWER: A
Rationale:
ACEi-associated cough is the most common adverse effect of ACE inhibitors, occurring in 5–20% of patients (with significant variation by ethnicity — Asian patients have rates of 30–40%). The mechanism is well-established: ACE (kininase II) is a dipeptidyl carboxypeptidase that normally degrades bradykinin and substance P in the airway mucosa. When ACE is inhibited, these kinins accumulate — stimulating sensory C-fiber afferents in the bronchial epithelium and triggering the cough reflex. The cough is characteristically dry, non-productive, and persistent, and does not resolve with continued ACEi therapy. Switching to an ARB is the definitive management: ARBs (losartan, valsartan, irbesartan, telmisartan, candesartan, olmesartan) block the AT1 receptor — the downstream target of angiotensin II — rather than the ACE enzyme. They do not inhibit bradykinin degradation (ACE remains functional) and are therefore not associated with cough. Cardiovascular and antihypertensive efficacy is equivalent between ACEi and ARBs for most indications. Cough resolves within 1–4 weeks of switching in the vast majority of patients.
Option B: Option B is incorrect because ACEi-associated cough does not resolve with continued therapy — it is a persistent pharmacological consequence of bradykinin accumulation that persists as long as ACE is inhibited.
Option C: Option C is incorrect because amlodipine does not cause pulmonary edema; CCB-associated edema is peripheral (dependent leg edema), not pulmonary.
Option D: Option D is incorrect because aliskiren inhibits renin but does not inhibit ACE — ACE remains functional, bradykinin degradation is preserved, and cough is not a known adverse effect; however, aliskiren is not recommended for combination with ACEi or ARBs (ALTITUDE trial demonstrated harm), and its use as a substitute is not standard practice.
Option E: Option E is incorrect because ACEi cough does not progress to hypersensitivity pneumonitis; it is a benign airway bradykinin-mediated adverse effect, not an inflammatory lung disease.
4. A 67-year-old man with hypertension and known stable coronary artery disease (prior PCI 3 years ago, on dual antiplatelet therapy) is admitted with acute ST-elevation MI. BP on presentation is 184/106 mmHg, heart rate is 88 bpm. He is taken for emergent primary PCI. Post-PCI, BP remains 172/102 mmHg. The interventional cardiologist asks the internist to address the blood pressure.
Which of the following most accurately identifies the pharmacological approach to blood pressure management in the immediate post-STEMI period?
A) IV sodium nitroprusside is the preferred agent for hypertension in the post-STEMI period — its combined preload and afterload reduction directly addresses the pressure overload contributing to infarct extension and is superior to other IV agents
B) IV nicardipine is the preferred agent for post-STEMI hypertension — DHP CCBs are the first-line antihypertensives in coronary artery disease and the IV formulation provides titratable control without negative inotropy
C) IV hydralazine is the preferred agent for post-STEMI hypertension — its selective arteriolar dilation reduces afterload without affecting heart rate; it is the safest agent in patients with recent MI because it does not affect AV conduction or myocardial contractility
D) IV high-dose metoprolol (15 mg IV in three 5 mg doses) should be given immediately for both rate and blood pressure control — IV beta-blockade within the first hour of STEMI is always beneficial and is guideline-mandated for all STEMI patients regardless of hemodynamic status
E) IV nitroglycerin is the preferred immediate agent — it reduces preload through venodilation (reducing left ventricular end-diastolic pressure and myocardial wall stress), provides coronary vasodilation (improving perfusion to the infarct border zone), and reduces afterload at higher doses; oral beta-blocker (metoprolol 25–50 mg) should be initiated within 24 hours when the patient is hemodynamically stable, providing anti-ischemic benefit, remodeling prevention, and long-term mortality reduction; DHP CCBs and hydralazine are not the preferred antihypertensives in the acute STEMI setting; non-DHP CCBs (verapamil, diltiazem) are contraindicated if LV function is reduced
ANSWER: E
Rationale:
Post-STEMI hypertension requires a pharmacologically targeted approach that addresses blood pressure while simultaneously providing myocardial protection. IV nitroglycerin is the first-choice IV antihypertensive in acute MI: at low doses it primarily produces venodilation (reducing preload, lowering left ventricular end-diastolic pressure, and reducing myocardial wall stress — the primary determinant of subendocardial oxygen demand); at higher doses it produces arteriolar dilation (reducing afterload); and it directly dilates coronary arteries, improving perfusion to the infarct border zone and reducing ischemia. Beta-blockers are the cornerstone of post-STEMI pharmacotherapy: ACC/AHA guidelines recommend initiating oral beta-blocker (metoprolol succinate or carvedilol) within 24 hours of STEMI in hemodynamically stable patients, with continuation for long-term remodeling prevention and mortality reduction. IV beta-blockade is not universally mandated — it carries risk of hemodynamic deterioration (cardiogenic shock, bradycardia, AV block) in patients with large anterior MI, reduced EF, or signs of heart failure, and should be used selectively. DHP CCBs (nicardipine) do not provide anti-ischemic benefit in acute STEMI and are not the preferred antihypertensives in this setting. Non-DHP CCBs are specifically contraindicated if LV function is reduced post-MI. Hydralazine causes reflex tachycardia that increases myocardial oxygen demand — specifically harmful in acute MI. Nitroprusside produces reflex tachycardia through baroreceptor activation and is not the preferred agent.
Option A: Option A is incorrect because nitroprusside causes reflex tachycardia, which increases myocardial oxygen demand in an already-ischemic heart.
Option B: Option B is incorrect because nicardipine (a DHP CCB) is not the preferred antihypertensive in acute MI; DHP CCBs can cause reflex tachycardia and are not anti-ischemic in this context.
Option C: Option C is incorrect because hydralazine causes marked reflex tachycardia — specifically harmful in acute MI by increasing myocardial oxygen demand.
Option D: Option D is incorrect because IV high-dose beta-blockade (COMMIT/CCS-2 trial) was associated with increased cardiogenic shock risk when given to all STEMI patients without hemodynamic assessment; it is not universally mandated in the immediate post-PCI period.
5. A 53-year-old woman with hypertension on valsartan 160 mg and hydrochlorothiazide 25 mg daily presents for a routine visit. Her home BP averages 152/94 mmHg — above target. She is adherent. Secondary causes are excluded. Her physician notes the regimen uses HCTZ rather than chlorthalidone and considers switching.
Which of the following most accurately explains the pharmacological basis for switching from HCTZ to chlorthalidone, and what BP improvement is expected?
A) Switching from HCTZ to chlorthalidone is contraindicated because the two diuretics have identical pharmacological mechanisms and switching would constitute an equivalent substitution with no clinical benefit; the more appropriate next step is to add a third drug class
B) Switching from HCTZ to chlorthalidone is indicated because chlorthalidone inhibits a different tubular transporter — it targets the NHE3 transporter in the proximal tubule rather than the NCC transporter; this proximal natriuresis provides greater sodium excretion and superior BP reduction
C) Switching from HCTZ to chlorthalidone is pharmacologically justified by chlorthalidone's superior pharmacokinetics — its half-life of approximately 40–60 hours versus HCTZ's 10–12 hours provides sustained 24-hour BP coverage including overnight, whereas HCTZ's short duration leaves significant portions of the 24-hour BP cycle uncovered; switching to an equivalent dose of chlorthalidone can reduce systolic BP by an additional 5–8 mmHg in patients previously on HCTZ; this pharmacokinetic difference also explains why cardiovascular outcome evidence was established with chlorthalidone (ALLHAT) and not with HCTZ
D) Switching from HCTZ to chlorthalidone is not supported by direct head-to-head randomized trials demonstrating improved cardiovascular outcomes; the switch should only be made if the patient has a specific intolerance to HCTZ
E) Switching from HCTZ 25 mg to chlorthalidone 25 mg is a like-for-like substitution with no expected change in BP, metabolic effects, or outcome — the two diuretics differ only in marketing and not in clinical pharmacology
ANSWER: C
Rationale:
While HCTZ and chlorthalidone share the same mechanism of action — inhibition of the NCC (sodium-chloride cotransporter) transporter in the distal convoluted tubule — they differ substantially in pharmacokinetics, and this difference has important clinical consequences. HCTZ has a half-life of approximately 10–12 hours, meaning its natriuretic and antihypertensive effect wanes significantly over the latter half of the dosing interval — leaving inadequate BP coverage during the overnight period and morning hours when cardiovascular event rates peak. Chlorthalidone's half-life of approximately 40–60 hours (reflecting its high volume of distribution through tight binding to carbonic anhydrase in red blood cells, which acts as a reservoir sustaining plasma levels) provides smooth, sustained 24-hour BP coverage including nocturnal BP. Observational studies and pharmacodynamic analyses suggest that switching from HCTZ to an equivalent dose of chlorthalidone produces an additional 5–8 mmHg systolic BP reduction in patients previously on HCTZ — attributable entirely to the superior coverage duration rather than any different mechanism. Additionally, the major cardiovascular outcome evidence for thiazide-type diuretics comes from chlorthalidone (ALLHAT, SHEP, MRFIT) — not from HCTZ — making chlorthalidone the evidence-preferred choice.
Option A: Option A is incorrect because while the mechanism is identical (NCC inhibition), the pharmacokinetic difference is clinically meaningful and makes the switch appropriate.
Option B: Option B is incorrect because both HCTZ and chlorthalidone inhibit the NCC transporter in the distal convoluted tubule — neither acts at the NHE3 transporter in the proximal tubule; this description is pharmacologically incorrect.
Option D: Option D is incorrect because while direct randomized head-to-head cardiovascular outcome trials comparing HCTZ and chlorthalidone do not exist, the pharmacokinetic rationale and the outcome evidence base supporting chlorthalidone provide sufficient justification for the switch.
Option E: Option E is incorrect because HCTZ and chlorthalidone differ importantly in half-life, 24-hour coverage, and outcome evidence — this is a clinically meaningful pharmacological difference, not a marketing distinction.
6. A 49-year-old man with hypertension is referred to a specialist after his BP remains at 168/102 mmHg on telmisartan 80 mg, amlodipine 10 mg, and chlorthalidone 25 mg daily. All doses are maximally tolerated. Adherence is confirmed by urine drug levels. ABPM confirms persistent hypertension. Secondary causes are excluded. PRA is 0.2 ng/mL/hr (suppressed) and aldosterone-to-renin ratio is 22. Potassium is 4.3 mEq/L. eGFR is 68 mL/min/1.73m2.
Spironolactone 25 mg daily is added. At 8 weeks, BP is 132/82 mmHg. At 6 months, the patient develops gynecomastia — tender breast tissue bilaterally — and requests an alternative.
Which of the following most accurately identifies the pharmacological basis of the gynecomastia and the best alternative?
A) The gynecomastia is caused by amlodipine — CCBs stimulate estrogen receptor activity in breast tissue through L-type calcium channel effects on estrogen synthesis; switching to a DHP CCB with lower lipophilicity (such as felodipine) will eliminate the gynecomastia
B) The gynecomastia is caused by telmisartan — ARBs with high PPARγ agonist activity (including telmisartan) stimulate adipose tissue estrogen production through peroxisome proliferator-activated receptor pathways, causing gynecomastia; switching to losartan will resolve the gynecomastia
C) The gynecomastia is caused by chlorthalidone — thiazide diuretics inhibit testicular androgen synthesis by blocking 17-alpha hydroxylase in Leydig cells; reducing the chlorthalidone dose to 12.5 mg will reduce the anti-androgenic effect
D) The gynecomastia is caused by spironolactone — its steroidal structure allows it to bind progesterone receptors and weakly block androgen receptors in breast tissue, reducing the androgen-to-estrogen ratio and stimulating breast tissue proliferation; the most appropriate alternative is eplerenone 25–50 mg twice daily — a selective non-steroidal MRA that does not bind androgen or progesterone receptors and therefore does not cause gynecomastia or other sex hormone-related adverse effects; eplerenone is approximately 60% as potent per mg as spironolactone and may require dose titration to maintain BP control; BP and potassium should be reassessed 4–6 weeks after switching
E) The gynecomastia is caused by chlorthalidone inducing secondary hyperaldosteronism, which drives excessive adrenal estrogen production; reducing chlorthalidone to 12.5 mg and adding spironolactone 50 mg will counteract the secondary aldosteronism and resolve the gynecomastia
ANSWER: D
Rationale:
Spironolactone-associated gynecomastia is a well-characterized, dose-dependent adverse effect occurring in approximately 10% of men on chronic therapy. The mechanism relates to spironolactone's steroidal chemical structure: as a synthetic steroid, spironolactone and its active metabolite canrenone can bind to progesterone receptors (stimulating progesterone-like effects in breast tissue) and weakly block androgen receptors, reducing local androgen activity relative to estrogen — shifting the androgen-to-estrogen balance toward breast tissue proliferation. The result is gynecomastia (and occasionally mastalgia). Other sex hormone-related adverse effects of spironolactone include erectile dysfunction, decreased libido, and menstrual irregularities in women. Eplerenone is the pharmacologically correct alternative: it is a selective mineralocorticoid receptor antagonist with minimal affinity for progesterone, androgen, and glucocorticoid receptors — its selectivity profile eliminates the hormonal adverse effects of spironolactone. Eplerenone is effective for resistant hypertension (though less studied in PATHWAY-2 directly, it shares the same MR-blocking mechanism) and is the recommended substitute when spironolactone causes anti-androgenic adverse effects. The key practical point is that eplerenone is approximately 60% as potent per mg as spironolactone, requires twice-daily dosing for optimal MR blockade (once-daily eplerenone has a shorter effective duration than spironolactone), and may require dose titration.
Option A: Option A is incorrect because amlodipine does not cause gynecomastia through estrogen receptor mechanisms; CCBs are not associated with gynecomastia.
Option B: Option B is incorrect because telmisartan's PPARγ agonist activity does not cause gynecomastia through estrogen production; this mechanism is not established clinically.
Option C: Option C is incorrect because thiazide diuretics do not cause gynecomastia through 17-alpha hydroxylase inhibition in Leydig cells; this mechanism does not exist for chlorthalidone.
Option E: Option E is incorrect because secondary hyperaldosteronism from chlorthalidone does not drive adrenal estrogen production sufficient to cause gynecomastia; this mechanism is pharmacologically implausible.
7. A 38-year-old woman with hypertension presents for medication review. She is on lisinopril 10 mg daily for newly diagnosed hypertension. She mentions she is planning to become pregnant within the next 6 months. Her BP is 136/86 mmHg on lisinopril. She has no CKD, no diabetes, and no proteinuria.
Which of the following most accurately identifies the appropriate antihypertensive management strategy given her pregnancy plans?
A) Continue lisinopril through the first trimester — ACEi are only harmful during the second and third trimesters (when fetal kidneys become active and dependent on the RAAS for development); stopping lisinopril in the first trimester is unnecessary
B) Switch lisinopril to a pregnancy-compatible antihypertensive now — given her plan to conceive within 6 months, lisinopril should be replaced with an agent safe throughout pregnancy before conception; appropriate substitutes include labetalol, methyldopa, or nifedipine extended-release; ACEi and ARBs are associated with fetal renotoxicity causing oligohydramnios, renal tubular dysgenesis, calvarial hypoplasia, and neonatal renal failure when taken during the second and third trimesters — and an unplanned first-trimester exposure is possible between conception and pregnancy confirmation; women of childbearing potential who may become pregnant should switch away from ACEi/ARBs proactively; BP should be reassessed 4 weeks after switching to confirm the alternative agent maintains adequate control
C) Continue lisinopril and add folic acid 5 mg daily — lisinopril is safe throughout pregnancy and the folic acid supplement protects against neural tube defects while providing cardiac benefit; the concern about ACEi in pregnancy applies only to high-dose therapy (above 20 mg daily of lisinopril) and not to the current dose of 10 mg
D) Switch to amlodipine 5 mg daily only — ACEi must be discontinued before conception, but the only appropriate replacement for a young woman planning pregnancy is a DHP CCB; labetalol, methyldopa, and nifedipine ER are not appropriate substitutes because they cross the placenta
E) No medication change is needed — at a BP of 136/86 mmHg on lisinopril, she is within the target range and all antihypertensive decisions can be revisited after a positive pregnancy test; changing medications preconceptionally is unnecessary and causes unnecessary regimen instability
ANSWER: B
Rationale:
This patient's pregnancy plans create an urgent need to switch away from lisinopril before conception. ACEi (and ARBs) are teratogenic during the second and third trimesters — they inhibit the fetal RAAS-dependent renal development, causing renal tubular dysgenesis, oligohydramnios (from fetal anuria), limb contractures, calvarial hypoplasia, and neonatal renal failure. The risk during the second and third trimesters is well-established and represents an absolute contraindication. First-trimester exposure is generally considered lower risk for renal toxicity (fetal kidneys are not yet RAAS-dependent for development), but the practical problem is that a woman who conceives while on lisinopril may not confirm pregnancy until 4–8 weeks into the first trimester — potentially during the embryonic organogenesis period when other teratogenic effects may also apply. For this reason, women of childbearing age who plan to become pregnant should switch to a pregnancy-safe antihypertensive before conception. The three guideline-endorsed options with the most robust pregnancy safety data are labetalol, methyldopa, and nifedipine extended-release. Amlodipine is accepted as an alternative CCB in some international guidelines but nifedipine ER has more pregnancy-specific evidence. Switching now — 6 months before planned conception — allows adequate time to confirm BP control on the new agent before pregnancy.
Option A: Option A is incorrect because while fetal renal toxicity is most pronounced in the second and third trimesters, the risk of unplanned first-trimester exposure and other potential embryonic effects supports preconceptional switching rather than waiting.
Option C: Option C is incorrect because ACEi teratogenicity is not dose-dependent — it is a class effect present at all therapeutic doses; and folic acid supplementation does not mitigate ACEi teratogenicity.
Option D: Option D is incorrect because labetalol, methyldopa, and nifedipine ER all cross the placenta (as does amlodipine) — placental crossing alone does not determine safety; all established pregnancy-safe antihypertensives cross the placenta and their safety profiles are based on human outcome data.
Option E: Option E is incorrect because waiting until a positive pregnancy test is confirmed risks second-trimester exposure during a period of established fetal renotoxicity.
8. A 71-year-old man with hypertension, type 2 diabetes, and stage 3b CKD (eGFR 36 mL/min/1.73m2, UACR 620 mg/g) is on lisinopril 40 mg, amlodipine 10 mg, and furosemide 40 mg daily. His BP is 154/92 mmHg. His nephrologist wants to add a fourth antihypertensive and considers spironolactone 25 mg daily. Potassium is 5.1 mEq/L.
Which of the following most accurately evaluates the safety of adding spironolactone at this stage and identifies the most appropriate management?
A) Spironolactone is relatively contraindicated at this stage — potassium of 5.1 mEq/L combined with eGFR 36 mL/min/1.73m2 (stage 3b CKD) in a patient on an ACEi creates a high-risk triad for life-threatening hyperkalemia; the ACEi-MRA combination in advanced CKD substantially impairs potassium clearance and the additive potassium retention places the patient at risk for potassium above 6.0 mEq/L; more appropriate alternatives for a fourth antihypertensive in this patient include bisoprolol (PATHWAY-2 second-best fourth-line option) or amlodipine dose assessment — if potassium binders (patiromer or sodium zirconium cyclosilicate) can be co-initiated to maintain potassium below 5.0 mEq/L, a cautious trial of low-dose spironolactone 12.5 mg could be considered under close monitoring in a specialist setting
B) Spironolactone 25 mg daily should be started immediately — potassium of 5.1 mEq/L is within the normal range and presents no contraindication to MRA initiation; ACEi and MRA combinations are routinely used in CKD without any additional monitoring requirements beyond routine follow-up
C) Spironolactone should be added at 50 mg daily — higher doses achieve more complete MR blockade and are more effective at reducing proteinuria in CKD; the higher dose outweighs the hyperkalemia risk at eGFR 36 mL/min/1.73m2
D) Spironolactone should be added but lisinopril should be reduced to 20 mg to make room for spironolactone's potassium-retaining effect — the combined potassium burden of full-dose ACEi plus MRA always requires ACEi dose reduction; potassium above 5.0 mEq/L on an ACEi is an absolute contraindication to full-dose lisinopril
E) Spironolactone is the only appropriate fourth-line agent per PATHWAY-2 regardless of potassium or renal function — withholding it based on potassium of 5.1 mEq/L is overly conservative; the cardiovascular and renal benefits outweigh the hyperkalemia risk in all patients with resistant hypertension
ANSWER: A
Rationale:
This patient presents the classic high-risk triad for ACEi-MRA-related hyperkalemia: advanced CKD (eGFR 36 mL/min/1.73m2, stage 3b), ACEi at full dose, and a potassium already at 5.1 mEq/L. In this context, adding spironolactone 25 mg carries meaningful risk for severe hyperkalemia: potassium above 6.0 mEq/L can cause life-threatening cardiac arrhythmias, and the combination of impaired renal potassium clearance (from reduced GFR) plus ACEi-mediated reduction of aldosterone (reducing potassium excretion) plus MRA blockade of the remaining aldosterone effect can produce rapid potassium accumulation. Guidelines generally recommend caution with MRA-ACEi combinations when eGFR is below 30–45 mL/min/1.73m2 and when baseline potassium is above 5.0 mEq/L. Alternative fourth-line options include bisoprolol (PATHWAY-2 demonstrated 4.5 mmHg systolic reduction, second only to spironolactone) or further optimization of existing agents. If the decision is made to use spironolactone given the patient's low PRA and proteinuric CKD (where MRA has additional renoprotective interest), co-initiating a potassium binder (patiromer or sodium zirconium cyclosilicate) to maintain potassium below 5.0 mEq/L is an emerging approach with evidence support — but this requires specialist-level close monitoring.
Option B: Option B is incorrect because potassium of 5.1 mEq/L at eGFR 36 with ACEi is not safely within the normal range for MRA initiation; this constitutes a high-risk scenario requiring careful assessment, not routine initiation.
Option C: Option C is incorrect because higher spironolactone doses carry even greater hyperkalemia risk at this eGFR; starting at 50 mg is inappropriate.
Option D: Option D is incorrect because reducing lisinopril dose is not a guideline-supported strategy for making room for spironolactone; and potassium above 5.0 mEq/L on lisinopril is not an absolute contraindication to continuing full-dose ACEi therapy — it is a caution signal.
Option E: Option E is incorrect because PATHWAY-2 enrolled patients with eGFR above 45 mL/min/1.73m2 and does not provide evidence for blanket use regardless of renal function and potassium; the cardiovascular benefit does not override patient safety.
9. A 44-year-old man with hypertension presents to his primary care physician for follow-up. He is on lisinopril 20 mg and amlodipine 5 mg daily, initiated 4 months ago. His office BP today is 148/94 mmHg. He reports checking his BP at the pharmacy — readings have ranged from 138 to 155 mmHg systolic over the past month. He mentions he always feels anxious in medical offices. His physician arranges 24-hour ABPM.
ABPM results: daytime average 128/82 mmHg; nighttime average 122/76 mmHg; 24-hour average 126/80 mmHg.
Which of the following most accurately identifies the diagnosis and the appropriate response?
A) This is masked hypertension — office readings are normal but home and ambulatory readings are elevated; the antihypertensive regimen should be intensified based on the ABPM findings
B) This is uncontrolled hypertension — the ABPM 24-hour average of 126/80 mmHg remains above the ABPM target of 120/75 mmHg; the antihypertensive regimen should be uptitrated to achieve the more stringent ABPM target
C) This is resistant hypertension — despite two antihypertensive agents at partial doses, his 24-hour average remains elevated; a third agent should be added before dose optimization is completed
D) This is true hypertension confirmed by ABPM — the daytime average of 128/82 mmHg exceeds the ABPM diagnostic threshold of 120/80 mmHg for daytime hypertension; the regimen should be intensified with a thiazide diuretic
E) This is white coat hypertension — the office BP is consistently elevated (148/94 mmHg) while the 24-hour ABPM average (126/80 mmHg) and daytime average (128/82 mmHg) are within normal ambulatory targets; no antihypertensive intensification is required; the current regimen is achieving adequate ambulatory BP control; the patient should continue current therapy with ABPM or home BP monitoring follow-up rather than office-based BP measurement alone, which is misleading in this patient; reassure the patient that the office-based readings do not represent his true daily BP burden
ANSWER: E
Rationale:
White coat hypertension is defined as consistently elevated office BP in the presence of normal out-of-office (ambulatory or home) BP. Diagnostic thresholds: office hypertension — above 140/90 mmHg (or 130/80 mmHg for high-risk patients); corresponding ABPM daytime threshold — 135/85 mmHg (the ABPM equivalent of office 140/90 mmHg). This patient's daytime ABPM average of 128/82 mmHg is below the ABPM daytime threshold of 135/85 mmHg, indicating normal daytime ambulatory BP. His nighttime average of 122/76 mmHg and 24-hour average of 126/80 mmHg are also within normal ABPM targets. The pattern — elevated office BP with normal ambulatory BP — fulfills the diagnostic criteria for white coat hypertension. The anxiety in medical settings and the consistently elevated office readings confirm the clinical suspicion. White coat hypertension is not entirely benign (it carries a mildly elevated cardiovascular risk compared to true normotension), but it does not require antihypertensive intensification beyond the current regimen. The appropriate management is to use ABPM or validated home BP monitoring as the primary guide for treatment decisions in this patient, rather than office measurements.
Option A: Option A is incorrect because masked hypertension is the reverse pattern — normal office BP with elevated ambulatory BP; this patient has elevated office BP with normal ambulatory BP.
Option B: Option B is incorrect because the ABPM 24-hour target of approximately 125–130/80 mmHg (the ABPM equivalent of office 130/80 mmHg for high-risk patients) is being achieved; the claim of an ABPM target of 120/75 mmHg is more stringent than current guideline recommendations.
Option C: Option C is incorrect because resistant hypertension requires three agents at maximally tolerated doses — this patient has two agents at partial doses, and his ambulatory BP is controlled; this is not resistant hypertension.
Option D: Option D is incorrect because the ABPM daytime threshold for diagnosis of hypertension is 135/85 mmHg, not 120/80 mmHg; a daytime average of 128/82 mmHg is below this threshold and represents controlled ambulatory BP.
10. A 66-year-old woman with hypertension on lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg takes aspirin 81 mg daily for primary cardiovascular prevention. Her physician starts spironolactone 25 mg as a fourth agent for resistant hypertension. At the 2-week follow-up, potassium is 5.0 mEq/L (borderline) and creatinine has risen from 1.1 to 1.4 mg/dL (eGFR from 62 to 48 mL/min/1.73m2).
Which of the following most accurately identifies the likely cause of the creatinine rise and the appropriate management?
A) The creatinine rise is caused by spironolactone-induced direct nephrotoxicity — MRAs cause renal tubular damage through aldosterone receptor-mediated oxidative stress in collecting duct cells; spironolactone must be permanently discontinued and the patient referred to nephrology
B) The creatinine rise is caused by amlodipine reducing renal perfusion pressure through its potent afferent arteriolar vasodilation — CCBs preferentially dilate afferent arterioles, reducing glomerular hydraulic pressure and GFR; amlodipine should be reduced to 5 mg
C) The creatinine rise most likely reflects a hemodynamic reduction in intraglomerular pressure from the combined volume-depleting (chlorthalidone, spironolactone's natriuretic effect) and efferent arteriolar dilating (lisinopril) effects — this is an expected pharmacological response rather than structural renal injury; a rise in creatinine of up to 30–35% from baseline is generally acceptable and may even indicate effective RAAS inhibition reducing intraglomerular hypertension; the patient should be assessed for signs of volume depletion (orthostatic symptoms, reduced urine output); potassium should be monitored closely; if the patient is volume-depleted, a modest reduction in chlorthalidone dose may help stabilize creatinine; structural nephrotoxicity should be suspected only if creatinine continues to rise beyond 30–35% or if other features of AKI develop
D) The creatinine rise is caused by lisinopril-induced bilateral renal artery stenosis — ACEi are the primary cause of renal artery stenosis in hypertensive patients; lisinopril should be immediately discontinued and replaced with amlodipine dose escalation
E) The creatinine rise indicates that spironolactone has caused a drug-drug interaction with chlorthalidone — the two diuretics compete for binding to the NCC transporter, producing paradoxical sodium retention and volume overload that reduces renal cortical perfusion; spironolactone should be replaced with eplerenone to avoid this interaction
ANSWER: C
Rationale:
A modest creatinine rise of approximately 27% (from 1.1 to 1.4 mg/dL) after intensifying antihypertensive therapy — adding a fourth agent in a patient on an ACEi, CCB, and thiazide — is an expected hemodynamic response rather than a sign of structural renal injury. The mechanism involves two components: volume depletion from chlorthalidone and spironolactone's combined diuretic effects reduces renal perfusion pressure; and lisinopril's efferent arteriolar dilation (reducing angiotensin II-mediated efferent constriction) lowers intraglomerular hydraulic pressure. Both effects reduce the glomerular filtration driving pressure, causing a hemodynamic reduction in GFR that manifests as a creatinine rise — the pharmacological equivalent of the expected "acute kidney injury" seen with ACEi initiation in high-risk patients. Importantly, a creatinine rise of up to 30–35% from baseline is generally considered acceptable and may even be a positive prognostic indicator — reducing intraglomerular hypertension is associated with long-term renoprotection. The clinical assessment should focus on volume status: if the patient is volume-depleted (orthostatic hypotension, reduced urine output, thirst), a modest reduction in chlorthalidone dose can be tried. Continued monitoring with the expectation of stabilization is appropriate. Structural nephrotoxicity should be considered only if creatinine rises beyond 35% or continues to rise without stabilizing.
Option A: Option A is incorrect because spironolactone does not cause direct nephrotoxicity through MR-mediated oxidative stress; the creatinine rise is hemodynamic.
Option B: Option B is incorrect because amlodipine preferentially dilates afferent arterioles, which in isolation would reduce intraglomerular pressure but is generally renoprotective in the context of concurrent efferent arteriolar dilation from ACEi; amlodipine is not the primary driver of the creatinine rise.
Option D: Option D is incorrect because ACEi do not cause renal artery stenosis; in fact, ACEi are used to treat hypertension in patients without bilateral RAS and are only avoided when bilateral RAS is already present.
Option E: Option E is incorrect because spironolactone and chlorthalidone act at different tubular sites and do not compete for the NCC transporter; spironolactone acts at the mineralocorticoid receptor in the collecting duct.
11. A 58-year-old man with hypertension and no other comorbidities presents to a new physician. His previous physician had him on lisinopril 40 mg, amlodipine 10 mg, chlorthalidone 25 mg, and spironolactone 50 mg daily — all confirmed at maximum tolerated doses. His home BP average is 162/98 mmHg. He is fully adherent by urine drug levels. ABPM confirms persistent hypertension. Secondary causes have been thoroughly excluded including primary aldosteronism (confirmed negative by saline suppression test). PRA is 0.6 ng/mL/hr (borderline normal). Potassium is 4.4 mEq/L. eGFR is 72 mL/min/1.73m2.
His new physician considers oral minoxidil as a fifth agent. Which of the following most accurately identifies the mandatory pharmacological prerequisites that must be in place before minoxidil is appropriate, and assesses whether those prerequisites are currently met?
A) Minoxidil requires only a loop diuretic as a co-prescription — the existing chlorthalidone and spironolactone together provide adequate diuresis equivalent to a loop diuretic; no beta-blocker is required because lisinopril provides sufficient neurohormonal suppression to prevent minoxidil-induced reflex tachycardia
B) Minoxidil has no mandatory co-prescription requirements at the 2.5 mg starting dose — prerequisites (beta-blocker and loop diuretic) are only required at doses above 10 mg daily; starting at the lowest dose allows assessment of efficacy before co-prescriptions are needed
C) Minoxidil requires a beta-blocker co-prescription only — the existing thiazide plus MRA combination provides adequate sodium retention management; a loop diuretic is not required if the combination of chlorthalidone plus spironolactone achieves adequate natriuresis
D) Minoxidil requires two mandatory co-prescriptions before initiation: a beta-blocker (to prevent reflex tachycardia from baroreceptor-mediated sympathetic activation) and a loop diuretic (to manage minoxidil's severe sodium and fluid retention); this patient's regimen lacks both; chlorthalidone and spironolactone combined are insufficient to manage minoxidil-associated sodium retention — a loop diuretic is specifically required; bisoprolol should be added to provide the mandatory beta-blockade; chlorthalidone should be switched to torsemide at an appropriate dose; once both are in place and the patient is re-evaluated for tolerability, minoxidil 2.5 mg daily can be initiated and titrated
E) Minoxidil is absolutely contraindicated in patients on ACEi — the combination of ACEi plus minoxidil causes irreversible inhibition of vascular smooth muscle KATP channels through a nitric oxide-mediated pathway, permanently impairing vasoconstriction capacity and causing irreversible hypotension
ANSWER: D
Rationale:
Oral minoxidil is one of the most potent oral antihypertensives available but has two non-negotiable co-prescription requirements that must be in place before initiation at any dose. First mandatory co-prescription — a beta-blocker: minoxidil's potent arteriolar vasodilation activates baroreceptors, triggering intense reflex sympathetic activation including tachycardia and increased renin release; without a beta-blocker, the reflex tachycardia substantially increases myocardial oxygen demand (potentially causing angina or MI) and the renin release amplifies secondary RAAS activation worsening fluid retention. A beta-blocker must be established before minoxidil is started. Second mandatory co-prescription — a loop diuretic: minoxidil causes profound sodium and fluid retention through secondary RAAS activation (renin → angiotensin II → aldosterone → sodium retention) and direct renal mechanisms; this sodium retention is frequently severe enough that thiazide-type diuretics (including chlorthalidone) and even MRAs alone cannot manage it adequately — a loop diuretic is specifically required. Assessing this patient's prerequisites: the regimen contains lisinopril (an ACEi, not a beta-blocker) and chlorthalidone plus spironolactone (thiazide plus MRA, not a loop diuretic). Neither prerequisite is met. Before initiating minoxidil: add bisoprolol (or another appropriate beta-blocker); switch chlorthalidone to torsemide (preferred for predictable bioavailability) at an adequate dose; spironolactone can be continued as it provides additional aldosterone blockade that complements the loop diuretic. Then initiate minoxidil 2.5 mg daily and titrate.
Option A: Option A is incorrect because lisinopril (an ACEi) does not prevent reflex tachycardia — tachycardia is mediated through beta-1 receptors, which only a beta-blocker can block.
Option B: Option B is incorrect because the co-prescription requirements apply at all minoxidil doses, including 2.5 mg; dose does not determine whether prerequisites are needed.
Option C: Option C is incorrect because the loop diuretic requirement is absolute — chlorthalidone plus spironolactone typically cannot manage minoxidil-associated sodium retention at this degree of severity.
Option E: Option E is incorrect because there is no pharmacological interaction between ACEi and minoxidil causing irreversible KATP channel impairment; this mechanism does not exist.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.